High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival.
about
EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytesEvolutionary determinants of cancerUpdate on acute myeloid leukemia stem cells: New discoveries and therapeutic opportunitiesMinimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical ApplicationsFunctional protein network activation mapping reveals new potential molecular drug targets for poor prognosis pediatric BCP-ALLCancer stem cell-directed therapies: recent data from the laboratory and clinic.Role of altered growth factor receptor-mediated JAK2 signaling in growth and maintenance of human acute myeloid leukemia stem cells.FISH+CD34+CD38- cells detected in newly diagnosed acute myeloid leukemia patients can predict the clinical outcome.Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia.Minimal Residual Disease in Acute Myeloid Leukemia: Still a Work in Progress?Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia.Identification and targeting leukemia stem cells: The path to the cure for acute myeloid leukemia.Targeting of CD34+CD38- cells using Gemtuzumab ozogamicin (Mylotarg) in combination with tipifarnib (Zarnestra) in Acute Myeloid Leukaemia.The transcription factor KLF4 as an independent predictive marker for pathologic complete remission in breast cancer neoadjuvant chemotherapy: a case-control studyAn orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells.A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children's Oncology GroupConcise review: preleukemic stem cells: molecular biology and clinical implications of the precursors to leukemia stem cellsModulation of A1 and A2B adenosine receptor activity: a new strategy to sensitise glioblastoma stem cells to chemotherapy.Proteomic profiling identifies distinct protein patterns in acute myelogenous leukemia CD34+CD38- stem-like cells.5-Fluorouracil chemotherapy of gastric cancer generates residual cells with properties of cancer stem cells.Right on target: eradicating leukemic stem cells.Direct confirmation of quiescence of CD34+CD38- leukemia stem cell populations using single cell culture, their molecular signature and clinicopathological implicationsHigh levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study.Hypoxia-inducible factors in cancer stem cells and inflammation.Cluster of differentiation 96 as a leukemia stem cell-specific marker and a factor for prognosis evaluation in leukemia.A role for GPx3 in activity of normal and leukemia stem cellsCD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900.Miniaturization applied to analysis of nucleic acids in heterogeneous tissues.Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8)Can immunotherapy specifically target acute myeloid leukemic stem cells?Preferential eradication of acute myelogenous leukemia stem cells by fenretinide.Xenograft models for the preclinical evaluation of new therapies in acute leukemia.ATP-binding-cassette transporters in hematopoietic stem cells and their utility as therapeutical targets in acute and chronic myeloid leukemia.The proportion of CD34(+)CD38(low or neg) myeloblasts, but not side population frequency, predicts initial response to induction therapy in patients with newly diagnosed acute myeloid leukemia.In vivo targeting of leukemia stem cells by directing parthenolide-loaded nanoparticles to the bone marrow niche.A tumor-related lymphoid progenitor population supports hierarchical tumor organization in canine B-cell lymphomaNovel mTOR inhibitory activity of ciclopirox enhances parthenolide antileukemia activity.Alantolactone selectively ablates acute myeloid leukemia stem and progenitor cells.Normal hematopoietic stem cells within the AML bone marrow have a distinct and higher ALDH activity level than co-existing leukemic stem cells.Discovery of potent parthenolide-based antileukemic agents enabled by late-stage P450-mediated C-H functionalization.
P2860
Q24604581-0E875CE0-A9FA-426A-93DD-4645D2206F6AQ26801710-6F8579B3-BF80-46FA-A986-9F115EEFED34Q28071384-A892377E-B1DF-4EC1-AD5F-09CDF2CEDB29Q28073464-A81EA42F-DE19-40DF-BFAE-5847DE93591DQ28475897-8EB149D6-54C0-4465-93F6-46CCA1057DDFQ33391372-7F964FE2-5EC9-4EC2-A522-0AF2E9C49513Q33556931-42BFDEFB-1C53-44E7-97A8-7EC599F12F96Q33641201-03D3E05E-E34C-442F-B83E-131756F99BDBQ33643108-601D3BE2-BDBA-407C-ABA9-D36FD761D573Q33832709-FE9C502D-F794-4CD3-B4F1-0BB6CA14EAF1Q33873844-6D0B1125-FB7D-4E11-A1F7-D86B5B6051AEQ34232877-16510772-BDEF-4764-B51F-9C697D29C06AQ34421932-15F0ABF5-136C-4B52-8A2D-12F7EFB6C9D6Q34434819-195ADF89-0030-4E93-8C54-71A2929F14E3Q34582568-36424598-5A33-4016-81C0-976BA6406DF3Q34585047-6E9BDC94-67D6-4A3B-8D97-128C46BE36B6Q34647637-80ED3CBE-FAA3-474E-94AD-15BDD34CE080Q34662274-C2E39534-23CC-4B3E-A8F1-1D2A0747F640Q35040064-BA11CA4A-3F94-49A5-AC31-8351C4AAF3CFQ35069199-6F648EA8-C288-4981-AFD3-6AC3A5EA3A86Q35132225-E71C1602-FD23-4E3C-996A-455D6DB6B1D6Q35344507-4DF93BEC-6304-4994-AEA5-A516CA7871ACQ35596914-BFE5F631-253F-4B3F-BBA6-723211F0C1CDQ35705992-2FA6F1E6-6BC0-47B9-84B6-1E92CDD83F89Q35803437-8BCAC94A-1A0E-4AC9-BB1F-E31C8BC59A6EQ35946153-07F73053-BD4A-4C0D-9435-AB80839921B1Q36249453-C81145DC-C19E-4F9C-8722-970C43D8A4F9Q36344100-0E093A22-ED0B-4A19-A75D-7DC6B4B9EE09Q36447920-F05962B3-6562-4445-B42B-D6ABA48BB072Q36694901-7F3F29FE-6462-4F40-A509-368F2909E294Q36747742-580BAF73-F2A1-44F9-B8AC-DEC5924A4F4AQ36799846-1981D6B4-B6EA-4D98-8CD8-C15A5CB52516Q36893545-6174DC43-1509-4074-A9C0-666D4674A019Q36995606-0F7045F3-10CA-453D-8894-D49966107D1DQ37014257-B3930662-875A-4576-B034-B722CDDCF5CFQ37193976-FADA4E4C-C055-4D6B-8204-F03FC00B8323Q37259702-86C005D3-652D-415C-A3A3-BD7F07447DB4Q37278653-4A452AE7-C508-475E-9B07-2316645E7992Q37297755-291F487C-1206-4F96-A390-A5903338FC95Q37522487-C7ABDCB8-FEFF-4FD3-82F6-7C9461D53224
P2860
High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
High stem cell frequency in ac ...... ual disease and poor survival.
@en
type
label
High stem cell frequency in ac ...... ual disease and poor survival.
@en
prefLabel
High stem cell frequency in ac ...... ual disease and poor survival.
@en
P2093
P1476
High stem cell frequency in ac ...... ual disease and poor survival.
@en
P2093
Angèle Kelder
Anna van Rhenen
August H Westra
Elwin Rombouts
Gerrit Jan Schuurhuis
Gert J Ossenkoppele
Marjolein A van der Pol
Nicole Feller
Sonja Zweegman
P304
P356
10.1158/1078-0432.CCR-05-0468
P407
P577
2005-09-01T00:00:00Z